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The molecular defect of uroporphyrinogen decarboxylase 
(UROD) was examined in a patient with mild hepato-
erythropoietic porphyria. To elucidate the UROD defect, 
we cloned UROD cDNAs from EBV -transformed lympho-
blastoid cells of the proband using reverse transcriptase-poly-
merase chain reaction. Nucleotide sequence analysis of the 
cloned UROD cDNAs revealed two separate missense mu-
tations, each occurring in a separate allele. One mutation was 
a VaP34 --+ Gin transition, and was due to three sequential 
point mutations (T417G418T419 --+ CCA); the other mutation 
was a His220 --+ Pro transition (A677 --+ C) . UROD pheno-
U roporphyrinogen decarboxylase (UROD) is the fifth enzyme in the heme biosynthetic pathway, and catalyzes the sequential removal of four car-boxyl groups from the carboxymethyl side chains in uroporphyrinogen to yield coproporphyrinogen 
[1]. Decreased activity of UROD is responsible for two of the pho-
tosensitizing forms of porphyria: porphyria cutanea tarda (PCT) 
and hepatoerythropoietic porphyria (HEP) [2]. In HEP, UROD 
activity is extremely low, leading to the speculation that HEP may 
be a homozygous form ofPCT [3-5]. 
HEP was first described by Gunther in 1967 [6], and some 20 
cases have been reported to date [2]. HEP is characterized clinically 
by severe photosensitivity, skin fragility, and hypertrichosis. Mark-
edly deficient URaD activity in patients with HEP was first re-
ported by Elder et al in 1981 [3] . In almost all cases of HEP, the 
catalytic activity of erythrocyte UROD was below 10% of the nor-
mal level [2,7,8] . Immunochemical studies have revealed three dif-
ferent kinds ofUROD proteins: i) cross-reactive immunologic ma-
terial (CRIM) negative [5]. ii) CRIM positive [8,9] , and iii) CRIM 
supernegative, i.e., a significant enzyme activity in the absence of 
detectable protein [7,10]. 
To date, three different point mutations and/or a deletion in the 
UROD gene have been described in three different families with 
HEP [11-13]. Recently we reported the first clinical, biochemical, 
and immunologic investigation of a three-generation family lineage 
with HEP [7 ,10]. The proband had characteristic signs of HEP, and 
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type studies demonstrated that the TGT --+ CCA mutation 
was inherited from the father, and the A --+ C mutation was 
inherited from the mother. In contrast to the null activity 
previously described for a mutant UROD from a patient with 
familial porphyria cutanea tarda, these mutant URODs had 
subnormal but substantial enzyme activities, when expressed 
in Chinese hamster ovary cells. This is the first demonstra-
tion of a mutation caused by three sequential base substitu-
tions. Key words: point mutation/compound heterozygosity. ] In-
vest Dermatol1 02:681- 685, 1994 
markedly decreased hepatic UROD activity «2% of normal) [7] . 
However, the proband was unique in that a) his erythrocyte UROD 
activity was decreased to only 16% of the normal control [7], b) his 
clinical features were milder than those of other patients [10] , and c) 
there was little detectable URaD protein in erythrocytes by radio-
immunoassay, rocket immunoelectrophoresis, or Western blot 
analysis [7,10]. Thus the UROD defect in erythrocytes of this pro-
band was due to CRlM-supernegative mutation [7] . 
To determine the molecular nature of the URaD defect in this 
patien~, we cloned and sequenced UROD cDNAs from his Epstein-
Barr VIruS (EBV) - transformed lymphoblastoid cells and identified 
separate point mutations in each URaD allele. 
MATERIALS AND METHODS 
The Proband and Family The proband was a 31-year-old man whose 
clinical and biochemical features have been described previously (10). 
Bnefly, he had marked skin fragility at 5 years of age, and a history of 
diag~osis as having "sun-allergy." He had markedly elevated uroporphyrin 
111 unne (= 20 tunes of the normal urper limit) and isocoproporphyrin in 
stool [10], the bIOchemical stigmata 0 the UROD deficiency [14). Erythro-
cyte UROD activity of the proband was 16% of the normal control value (7), 
whereas the quantity ofimmunochemically detectable UROD protein in his 
erythrocytes was below the detection limit of the assay (7% of the normal 
control) (7) . 
Cloning and Sequence Analysis ofUROD cDNAs Isolation of lym-
phocy.tes, transformation of cells with EBY, and cultivation of Iympho-
blastOid cells were carried out as described previously [15). Poly(A) +RNA 
isolated from EBY-transformed Iymphoblastoid cells [1 6,17) was used for 
synthesis of cDNA by using SuperScript RNaseH- reverse transcriptase 
(Gibco-BRL, Gaithersburg, MD) primed with 0Iigo(dT)t2_ tB (Pharmacia 
Fine Chemicals, Uppsala, Sweden). Amplification of the entire coding re-
gion of UROD cDNAs was carried out using the following two synthetic 
oligonucleotides as polymerase chain reaction (PCR) primers: URODl , 
5'-CCGGAATTCCAGACAGCTGACCATG-3' (nucleotides 6-21 of 
the original human UROD cDNA sequence) [18] and UROD2, 5'-CATC-
TAGATTAGTGGTACTTGAGGG-3' (nucleotides 1136-1152) [1 8]. 
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PCR was carried out using a DNA Thermal Cycler (Perkin-Elmer-Cetus 
Corp., Norwalk, CT) as described previously [19]. PCR products were 
digested with EeoRI and Xbal and cloned into pGEM-4Z vector (Promega 
Corp., Madison, WI). Appropriate restriction fragments ofUROD cDNAs 
were subcloned into pGEM-4Z vectors. DNA sequence analysis was carried 
out by the dideoxy chain-termination method using a genetically engineered 
T7 DNA polymerase (Sequenase version 2.0; United States Biochemical 
Corp., Cleveland, OH) [20-22]. Sequence data were analyzed using 
DNASIS software (Hitachi, San Bruno, CAl. 
Phenotype Studies UROD phenotype analyses in the HEP family were 
carried out by PstI restriction fragment-length polymorphism (RFLP) and 
dot hybridization using allele-specific oligonucleotides (ASOs) . Using 
1 - 5 f.lg of total RNA isolated from EBV-transformed lymphoblastoid cells 
and random hexamers, UROD cDNA corresponding to positions 277-
1153 was amplified by reverse transcriptase (RT)-PCR. PCR products, puri-
fied using the GeneClean kit, were digested with PstI and analyzed by 
agarose gel electrophoresis. Genomic DNAs from lymphoblastoid cells of 
HEP family members were prepared by a standard method for high-
molecular-weight DNA isolation [23]. DNA fragments corresponding to 
exon 5 of the UROD gene were amplified using appropriate primers and 
genomic DNAs as templates. PCR products were blotted onto a sheet of 
Zeta-probe blotting membrane (Bio-Rad Laboratory, Richmond, CAl ac-
cording to the protocol described by the manufacturer. Hybridization with 
ASOs was performed as described previously [24]. 
Expression of Mutant UROD cDNAs The expression vector pdKCR-
Neo [24], which contains the SV40 early gene promotor, donor, and accep-
tor sites, and polyadenylation sites derived from the rabbitp-globin gene and 
the SV40 early gene, was used for expression ofUROD proteins. The XbaI 
site of cloned UROD cDNA was converted to an EcoR! site by using XbaI-
XmllI and EcoRI-Xl1ItII adapters (Clonetech, Palo Alto, CAl and inserted 
into the unique EcoRI site of the pdKCR-Neo vector. The recombinant 
plasmids were introduced into Chinese hamster ovary (CHO) cells by co-
precipitation with calcium phosphate (CellPhect Transfection kit; Pharma-
cia Fine Chemicals), followed by selection with G418 (Geneticin; Gibco-
BRL) (800 J.Lg/ml) starting 24 h after transfection. 
Western Blot Analyses The human UROD protein in lymphoblastoid 
cells and in CHO cells were specifically detected by Western blot analysis as 
described previously [25]. UROD in the cytosol fraction from 108 cells was 
partially purified using a 1 X 3-cm column by diethylaminoethyl (DEAE) 
cellulose chromatography [1], and concentrated approximately a hundred-
fold by a Minicon concentrator B (Amicon, Inc., Beverly, MA) at 4°C. 
One-hundred-fifty micrograms of protein were loaded onto each lane in 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) in 
a 10% gel that was blotted onto a sheet of nitrocellulose; detection of the 
specific immune complex was carried out using an enhanced chemilumines-
cence assay [26]. The antibody used in this study was rabbit immunoglobulin 
G (IgG) purified from a monospecific polyclonal antiserum against human 
UROD ll]. 
UROD Assay UROD activities were determined using 106 cells per assay 
by a high-performance liquid chromatography (HPLC) method with penta-
carboxylate porphyrinogen III as substrate [1]. 
RESULTS 
UROD Activity and UROD Protein in EBV-Transformed 
Lymphoblastoid Cells The father (II in Fig lA), the mother 
(12)' and three children (III\> III2, and III3) of the proband had ap-
proximately one-half the normal control level of UROD activity 
and UROD protein content in their EBV -transformed Iymphoblas-
toid cells (Fig 1). These results are consistent with findings in their 
erythrocytes [7] and indicate that these individuals are heterozygous 
for UROD deficiency. In contrast to these subjects, the proband 
(III) had 4% of normal control UROD activity and 3% of control 
UROD protein concentration (Fig 1). His UROD defect in EBV-
transformed Iymphoblastoid cells is therefore more compatible 
with a CRIM negative than with the supernegative mutation ob-
served in his erythrocytes [7). 
Southern and Northern Blot Analyses Southern blot analysis 
of the UROD genomic DNA of the proband and his parents 
showed restriction fragments identical to those from three norihal 
subjects (n = 3) (data not shown). These results suggest that there is 
no large deletion or rearrangement in the UROD gene in this 
family. UROD mRNA examined by Northern blot analysis was 
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normal in its level of expression and its size in all subjects in this 
pedigree (data not shown). These results concur with the implica-
tions from the Southern blot analysis that the UROD defect in this 
family is probably due to a point mutation(s). 
Cloning and Identification of Mutation(s) of the UROD 
Gene in the Proband To delineate the mutation(s) of the 
UROD gene in the proband, cDNAs were synthesized by reverse 
transcription using poly(A+) RNA isolated from EBV-transformed 
Iymphoblastoid cells of the proband. UROD cDNA fragments, 
which included the entire protein coding region, were amplified by 
PCR and cloned into pGEM4Z vectors. To confirm the results, 
amplification by RT-PCR and cloning of UROD cDNAs were 
performed independently three times. Nucleotide sequence analysis 
of the cloned UROD cDNAs of the proband revealed two separate 
point mutations. We termed one the Ul mutation; it was three 
sequential base substitutions, T417G418T419 -+ CCA, which resulted 
in a VaP34 to Gin change (Fig 2). The other mutation, U2, was a 
A677 -+ C transition, which resulted in the change ofHis220 -+ Pro. 
The U2 mutation also created a new Pst! site in the allele (Fig 2). 
There were four additional base substitutions found in both alleles, 
A. 
I 2 
44% 49% 
II 
4% 
III 2 
39% 42% 67% 
B. 
UROD --
/ 
Figure 1. Pedigree of a family with HEP and immunoquantifiable protein 
in EBV -transformed lymphoblastoid cells. A) The pedigree tree of the fam-
ily, based on UROD activity [10]. The proband (lIt) is indicated by an arrow. 
UROD activity in EBV-transformed lymphoblastoid cells is shown as per-
centage of normal control (mean ± SEM, 175 ± 7 pmol coproporphyrino-
gcn formed/mg protein/h; n = 3). B) Western blot analysis of the UROD 
protein levels of EBV -transformed lymphoblastoid cells. Immunoquantifi-
cation of UROD was carried out as described in Materials alld Met/lods. Std, a 
purified UROD preparation from normal human erythrocytes. 
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Figure 2. Mutations responsible for the UROD defect in the proband. 
UROD cDNAs were amplified by RT-PCR from the proband's poly(A)+ 
RNA and cloned. Bases and amino acids involved in substitutions are high-
lighted in bold letters and the substitution is marked with an asterisk. A) U1 
mutation: T417G4'8T4'9 -> CCA, resulting in one amino acid change, 
Va!,34 --> GIn. B) U2 mutation: A677 -> C, resulting in an amino ac id 
change, His220 -> Pro. C) Point mutations ofUROD cDNAs found in the 
proband are summarized. A325 -> G is an established polymorphism [18]. 
one of which, A32s ~ G, was an established polymorphism [18]; 
others were silent mutations. These results are summarized in Fig 2. 
All clones had either U1 or U2 mutations, but not both, indicating 
that the U1 and U2 mutations occur on separate alle les. The results 
of direct sequence analyses also confirmed that the proband had 
both the UI and U2 mutations, w hereas the father had the UI and 
the mother had the U2 mutation . 
Phenotype Studies The mode of inheritance of these mutations 
in this family was studied. The existence of the UI mutation was 
determined using dot-blot hybridization with an ASO probe, 
whereas the U2 mutation was studied by Pst! restriction fragment-
length polymorphism (RFLP) analysis. Amplified genomic DNAs 
corresponding to exon 5 of the UROD gene from the family mem-
bers were hybridized with oligonucleotide probes specific to the UI 
mutation or the normal UROD sequence. Genomic DNA samples 
amplified by PCR from the proband, the father, and the youngest 
child h ybridized with the UI-specific oligomer, but not with the 
sample from the mother, nor with those of the two elder children 
(Fig 3A) . All these subjects hybridized with the normal UROD 
ASO, indicating that these subjects had a normal sequence in the 
corresponding allele. 
Because the U2 mutation created a new Pst! site in the allele, 
RFLP analysis with Pst! w;!s used to identify the U2 mutation in the 
members of the family. UROD cDNAs were amplified by PCR, 
digested with Pst!, and separated by agarose gel electrophoresis. 
Results showed that cDNAs from the proband, the mother, and the 
two elder children were positive for the new PstI cleavage site, 
indicating that they were positive for the U2 mutation, whereas the 
father, the youngest child, and a normal subject were negative (Fig 
3B). These results demonstrate that the Ulmutation was inherited 
from t~e father of the proband and the U2 mutation from the 
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A. Dot-blot hybridization with ASO 
5' -CT AGGCT ATGTGTTCCAAG-3' 
S'-CTAGGCTACCAGTTCCAAG-3' 
B. Pstl RFLP 
"" 
~ :: -------
...___ 877 
- 49' 
'-- )86 
A new PstI si te formed by U2 mutation 
Am 
S'---I 
I $ r-J' 
Ps,l PSII 
I: 877 :/ 'I· PCR produCI 386 491 
Normal ASO 
Ul ASO 
Nomlal ASO 
Ul ASO 
Figure 3. UROD phenotype studies. A) Dot-blot hybridization with 
ASOs. PCR-amplified fragments of the UROD genomic DNA correspond-
ing to exon 5 were dot-blotted onto a sheet of Zeta-probe membrane and 
hybridized with the 32P-labeled normal and U1-ASO (U ,). The subject code 
number IS IdentIcal to that described in Fig 1. pUROD-U1, cloned Ul 
eDNA; pUROD-N, cloned normal cDNA. B) Pst! RFLP for the U2 defect. 
AYROD cDNA fragment (877 bp) was amplified by RT-PCR, digested 
With Pst!, and separated by agarosc gel electrophoresis and visualized by 
ethidium bromide staining. M1, cpXl74DNA/Hi"fI digest; M2, ADNA-
HlI1dIII/cpX174RF DNA-HaeIII digest; N. A normal subject; other lanes 
are the same as in A). 
mother. The proband's children inherited either the UI or the U2 
mutation, but not both. 
UROD Activity Expressed by the Mutant UROD cDNAs 
Mutant UROD cDNAs were expressed by transfection into CHO 
cells and results were compared with those obtained by transfection 
of the normal UROD eDNA. Human UROD protein expressed in 
CHO cell s was quantified by Western blot analysis using a mono-
specific rabbit IgG for human UROD. Human UROD activity was 
calculated as the difference between the total enzyme activity and 
the activity of mock transfection, which was normalized on the 
basis of the human UROD protein content and expressed as an 
activity jmass ratio. CHO cells transfected with normal UROD 
eDNA were found to express significant human UROD activity 
compared to those that were mock-transfected. The activity jmass 
ratio of the protein expressed by transfectiol1 of the UI eDNA was 
=80% of that of the normal eDNA, whereas the activity of the 
protein derived from the U2 eDNA was only 40% of the normal 
control (Fig 4). These experiments were repeated twice, 2 weeks 
apan, for all transfectants, and similar resu lts were observed in both 
experiments. 
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Figure 4. Expression of UROD cDNAs in CHO cells. Normal and the 
mutant UROD cDNAs were introduced into a pdKCR-Neo expression 
vector. The recombinant and the mock construct were transfected into 
CHO cel ls and quantification of the human UROD protein and UROD 
activity assays were carried out as described in Materials alld Met/rods. The 
basal level of UROD activity in CHO cells in mock-transfected cells was 
negligible and no UROD protein was detectable by Western blot analysis. 
Data arc the mean of three separate determinations. C, with mock construct, 
U1, with U1 cDNA; U2, with U2 eDNA; N, with normal UROD cDNA. 
DISCUSSION 
The results of our study show that the proband with HEP in this 
family carried a compound heterozygous defect of the UROD gene. 
Two distinct mutations were detected in UROD cDNAs from the 
proband (U1 and U2), each occurring in a separate allele. Whereas 
the U2 mutation was a single base transition, A677 --> C, resulting in 
a change from His220 --> Pro, the U1 mutation was a substitution of 
three sequential bases (T417G418T419 --> CCA), which, however, re-
sulted in only one amino acid change (Val 134 --> Gin). Neither mu-
tation identified in the proband has been described in other patients 
with HEP [11-13] or in pat ients with familial PCT [27,28]. In 
addition, three sequential base substitutions with a resultant amino 
acid change have not been described previously. 
Phenotypic studies have confirmed these mutations and estab-
lished that the Ul mutation was inherited from the proband's father 
and the U2 mutation was inherited from the proband's mother. 
C hildren of the proband inherited either the U 1 or the U2 mutation 
from the proband, but not both. Thus the proband, who was clini-
cally and biochemically compatible with a homozygous defect of 
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UROD, has been shown to be a compound heterozygote for two 
separate UROD gene defects . As shown in Table I, homozygous 
UROD defects have been described in two families with HEP 
[11,12] and a compound heterozygosity between a missense point 
mutation and a large gene deletion was described in another family 
[13]. The patient with the homozygous mutation had a single base 
substitution within the coding sequence leading to the replacement 
of a glutamic acid by a lysine at codon 167 [12]. These findings 
indicate that there is marked heterogeneity in the molecular basis of 
the pathogenesis of HEP. 
This study also represents the first expression of mutant UROD 
cDNAs of HEP in a heterologous system. Previously, only mutant 
UROD from a patient with familial PCT had been studied in a 
bacterial expression system; no enzyme activity was detected [27]. 
Our results indicate that enzyme activity was reduced by = 20% by 
the U 1 mutation and = 60% by the U2 mutation. Decreased en-
zyme activity by the U2 mutation involving a histidine substitution 
is consistent with the proposed role of histidine for enzyme activity 
[29] . Valine at residue 134, altered by the U1 mutation, is a highly 
conserved residue throughout the phylogeny [13,30], and thus may 
be important for catalytic activity. On the other hand, these UROD 
activities were still significantly higher than the null activity de-
scribed for the bacterially expressed UROD from a patient with 
PCT [27] . The enzyme proteins encoded by U1 and U2 mRNAs 
showed no appreciable change in turnover rates as compared with a 
normal control in vitro (data not shown) . This finding is in contrast 
to the marked instability of mutant UROD reported in two other 
families with HEP [11,12] or familial PCT [27,28]' but is similar to 
that observed in another family with HEP recently described by de 
Verneuil et al. [13] . These patients with normal enzyme stability 
nonetheless had markedly decreased UROD activity in erythro-
cytes [13] and, as shown in our patient, in lymphocytes. The reason 
for the discrepancy between the property of the enzyme studied 
ill vitro and that in villo in cells is unclear at present. However, it has 
been shown that 5l1ch differences exist also for other proteins [31]. 
The fact that the UROD mutations found in HEP, including 
those found in our proband, have not been detected in familial PCT 
[12,13,32] suggests that mutations may be different in these dis-
eases, and that HEP may not be a homozygous form of familial peT 
[12,27]. However, the conclusion on this point is not possible until 
more mutations in familial peT are clarified. The difference in the 
catalytic activity of UROD in peT and HEP also suggests that the 
mutations found in peT may result in a severe enzymatic defect, 
whereas the mutations found in HEP are milder and can occur either 
as a homozygous or a compound heterozygous defect. 
Our proband had a markedly decreased UROD activity in lym-
phocytes (4%) and the liver (2%) [7], but there was significant 
UROD activity in his erythrocytes (16%) [7]. The discrepancy in 
UROD activities between erythroid and non-erythroid cells in the 
proband may suggest the possible existence of tissue-specific iso-
Table I. UROD Mutations/Deletions Reported in HEP and Familial PCT 
Disease Mutation/Deletion 
HEP Gly2S! ~ Glu 
HEP Glu!67 -+ Lys 
HEP Arg292 -+ Gly 
HEP Large deletion 
HEP Val''' -+ GIn 
HEP His220 ~ Pro 
f-PCT Gly2S! -+ Val 
f-PCT Exon 6 deletion 
.. Exa.mined in vitro. 
• UROD activity in hemolysate. 
<.J A compound heterozygote. 
Allelic 
Status 
Homo 
Homo 
Hetero 
Hetero 
Hetero 
Hetero 
Hetero 
Hetero 
Character of Mutants' 
UROD Activity 
in Lymphocytes Stability Activity References 
= 5% Decreased Unknown [34) 
= 10% Decreased Unknown [1 2J 
6.3-8.3%' Normal Unknown [13]' No product 
= 4% Normal = 80% This paper! Normal = 40% 
= 50% Decreased Unknown [28] 
----
= 50% Decreased = 0% [27,35] 
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zy m es, and in fact the erythroid- and non-specific UROD isozymes 
have been suggested [33J. However, genetic evidence suggests that 
there is a single transcript for this enzyme in all tissues so far exam-
ined, and that the gene copy of this enzyme is probably one per 
haploid genome [18] . The apparent supernegative CRIM in the 
proband's ery~hrocytes may be du~ to a loss o~ an epitope. However, 
it appears unlikely because the antibody used 111 ti1lS study was poly-
clo nal. Alternatively , it could be due to insensitivity of the immu-
no chemical assays, compared with the sensitivity of enzyme activity 
assays. Further studies are needed to clarify these questions. 
The unique feature of this study is the novel three sequential base 
substitutions in the UROD eDNA of the proband, which resulted 
in a change of one amino acid with only a moderate effect on 
UROD activity . Our studies, as wel l as work by others, underscore 
the marked genetic heterogeneity in this rare inherited disorder of 
heme biosynthesis. 
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